An Introduction to Pulmonary Hypertension
With advancements in pulmonary hypertension (PH) pathobiology over the past 20 years, more than a dozen therapies are available for the treatment of pulmonary arterial hypertension and chronic thromboembolic PH. Efforts have focused on identifying novel pathogenic targets towards the development efficacious, disease-modifying therapies. There is currently a surge in the development of novel agents, including those to rebalance bone morphogenetic protein receptor type II (BMPR-II) signalling, stimulate soluble guanylate cyclase and inhibit the nuclear factor-kappa B (NF-κB) pathway.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever changing landscape
Our supporting partners do not constitute an endorsement of the content on this page.
Pulmonary Hypertension Content
Treatment decisions for the use of medical therapy in patients with CTEPH
In this activity, watch leading expert Prof. Marc Humbert explore the latest approaches to optimizing clinical management of CTEPH, including medical therapy strategies to better support treatment goals alongside the importance of risk assessment-based treatment decisions. The impact of new and emerging data surrounding use of medical therapies in CTEPH will also be appraised.
- Discuss the disease management options for patients with CTEPH whose treatment goals are not met with their current regimen
- Perform appropriate risk assessments when making treatment decisions for patients with CTEPH
- Describe the new and emerging data for the use of medical therapy in patients with CTEPH, which can inform treatment decisions
Medical therapy for CTEPH: New data new horizons
Watch this two-part activity discussing the latest developments in the use of medical therapy for the management of CTEPH. Filmed following CHEST 2020 and ERS 2020. Part 1: Watch internationally renowned expert Prof. Joanna Pepke-Zaba review key data from the congresses Watch Now Part 2: Choose from leading experts who discuss what the latest data mean for global and regional practice Select An Interview
- Recall the new and emerging data around patient and disease characteristics in order to select the optimal treatment strategy for each individual patient
- Interpret new and emerging data for medical therapy and their impact on daily clinical practice
- Assess the latest changes to best practice for the care of patients with CTEPH
Medical therapy for CTEPH: What is the standard of care in 2020?
Watch a panel of world-leading experts discuss the multidisciplinary approach to the diagnosis and treatment of CTEPH, including emerging targeted medical therapies for technically inoperable patients.
- Discuss best practice for the multidisciplinary assessment of CTEPH
- Apply medical therapy for inoperable patients with CTEPH
- Perform medical therapy for patients with post-operative persistent/recurrent symptomatic disease
Medical therapy for CTEPH: From biology to new treatment options
Watch leading experts involved in the care of patients with CTEPH discuss the latest issues and controversies in the medical management of CTEPH and related comorbidities, including the evolving data supporting the use of oral therapy, the application of oral therapies in clinical practice and how the underlying biology impacts on treatment decisions.
- Describe the biological and pathophysiological mechanisms of CTEPH
- Summarize the evolving data supporting the use of oral therapies
- Explain how new developments in medical therapy for the treatment of CTEPH will change daily practice
Luis Jara Palomares, ERS 2019 – Environmental Factors in Pulmonary Embolism and PAH
Luis Jara-Palomares, from Seville, Spain, joins us at ERS 2019 in Madrid, to discuss the main findings from his study into the significance of environmental factors in pulmonary embolism and pulmonary arterial hypertension. Questions 1. What are the major causes of pulmonary embolism and pulmonary arterial hypertension? (0:06) 2. What is known about the impact […]
Sandeep Sahay, ATS 2019 – New World Symposium Proceedings on Pulmonary Hypertension
Sandeep Sahay (Houston Methodist Lung Center, Houston Methodist Hospital, Houston, TX, USA) speaks from the 2019 ATS conference in Dallas, TX, USA about portopulmonary hypertension, how it differs from other types of hypertension and changes to the diagnostic criteria. He also addresses the changes this will have on patients and addressing unmet needs in hypertension. […]
James R Klinger, CHEST 2018 – Management of pulmonary arterial hypertension
James R Klinger (Rhode Island Hospital, and Warren Alpert Medical School, Brown University, Providence, RI, US) chats to us on the topic of his session entitled: Current Quandaries in Pulmonary Arterial Hypertension (PAH) Management. Questions 1. What are the major challenges in the management of pulmonary arterial hypertension (PAH)? (0:10) 2. What have been the […]
Namita Sood, CHEST 2018 – Pulmonary arterial hypertension: diagnosis and current therapies
Namita Sood (University of Texas Health Science Center, Houston, TX, US) discusses challenges and advances in pulmonary arterial hypertension (PAH). Questions 1. What is the definition of pulmonary arterial hypertension (PAH)? (0:10) 2. What are the major challenges in the diagnosis of PAH? (0:43) 3. How is PAH classified and what are the most important […]
Pulmonary Arterial Hypertension Management – A New Approach For a Rare Disease
European Respiratory & Pulmonary Diseases, 2016;2(2):50–1 DOI: //doi.org/10.17925/ERPD.2016.02.02.50
Pulmonary arterial hypertension (PAH) is a rare, deadly and incurable condition.1 With a five-year survival rate below 60%, the outcome of this disease is not any better than that of many cancers.1,2 However, numerous treatment options are currently available: more than 20 randomised controlled trials (RCTs) have been conducted over the past 10 years, allowing […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!